nausea after tirzepatide injection Managing Post-Injection and Discomfort GLP-1 Nausea: How to Relieve

Patients with established cardiovascular disease (heart attack, stroke history) who benefit from semaglutides proven MACE reduction (SELECT trial) Adolescents aged 1217 with obesity Wegovy is the only approved GLP-1 option in this age group Patients who prefer or need an oral medication option (Rybelsus tablets for type 2 diabetes) Those for whom semaglutide is more affordable or better covered by insurance Patients with metabolic dysfunction-associated steatohepatitis (MASH) Wegovy HD received approval for this indication in 2025 First-time GLP-1 users who want to start with the medication with the longest real-world safety track record Frequently Asked Questions Is tirzepatide stronger than semaglutide

Not low

Concentration ties mass to volume

Each marking represents 1 unit, and each unit equals 0.01 mL

Injecting into areas with adequate subcutaneous fat, rotating injection sites to prevent tissue irritation, and avoiding injection site reactions all contribute to more predictable drug delivery

Semaglutide does not target muscle tissue